Study guide

10.2 Expedited Reporting and the Sponsor Awareness Clock

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

10.2 Expedited Reporting and the Sponsor Awareness Clock

Key Takeaways Explain This Topic AI

E2A fatal/life-threatening unexpected suspected reactions require notification within seven calendar days.

Follow-up for that route is as complete as possible within eight additional calendar days.

Other serious unexpected suspected reactions have a maximum fifteen-calendar-day initial reporting timeframe.

Last updated: October 2026

Expedited Reporting and the Sponsor Awareness Clock

A Suspected Unexpected Serious Adverse Reaction (SUSAR) represents the highest tier of urgent safety concern in clinical drug development. A safety event qualifies as a SUSAR only when it satisfies all three of the following independent criteria simultaneously:

Serious: The event meets at least one of the six regulatory seriousness criteria (results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, causes persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event).

Suspected Related (Adverse Reaction): There is at least a "reasonable possibility" of a causal relationship between the investigational product and the adverse event, as assessed by either the Principal Investigator or the sponsor.

Unexpected: The nature, severity, specificity, or outcome of the reaction is not consistent with the applicable Reference Safety Information (RSI) located in the Investigator's Brochure or approved package insert.

Why SUSARs Demand Expedited Action

SUSARs represent critical changes in the known benefit-risk balance of an investigational medicinal product (IMP). Because the reaction was not previously anticipated in the Investigator's Brochure, neither the regulatory authorities, the Institutional Review Boards / Independent Ethics Committees (IRBs/IECs), nor the participating trial subjects were informed of this potential hazard during trial approval and informed consent. Consequently, health authorities require rapid, expedited reporting so they can evaluate whether other ongoing studies using the same molecule must be paused, amended, or terminated.

Expedited Regulatory Reporting Timelines: ICH E2A

The International Council for Harmonisation guideline ICH E2A establishes globally accepted expedited reporting timeframes. These standards are codified into national regulations, including US FDA 21 CFR 312.32 and European Union guidelines.

The Fatal or Life-Threatening Timeline: The "7 + 8 Calendar Day Rule"

When an unexpected adverse reaction results in death or is immediately life-threatening , the regulatory reporting clock accelerates:

Initial Expedited Notification (Within 7 Calendar Days):

The sponsor must notify regulatory authorities (e.g., FDA, EMA, PMDA) as soon as possible, and no later than 7 calendar days after initial receipt of the qualifying information by the sponsor.

This initial report may be preliminary (via electronic submission or secure safety portal), but must contain minimum essential reporting details.

Complete Written Follow-up Report (Within an Additional 8 Calendar Days):

The sponsor must submit as complete a follow-up report as possible within an additional 8 calendar days following the initial 7-day notification (often referenced as Day 7 + 8 = 15 calendar days total from original awareness).

The follow-up report should include available follow-up and an assessment of the finding's significance; actively seek missing information.

All Other Serious, Unexpected Reactions: The "15 Calendar Day Rule"

For all other serious, unexpected reactions that are neither fatal nor immediately life-threatening (e.g., resulting in initial or prolonged inpatient hospitalization, persistent disability, congenital anomaly, or requiring medical intervention):

Comprehensive Written Report (Within 15 Calendar Days):

The sponsor must file an initial safety report with the minimum information, followed by updates to regulatory authorities as soon as possible, and no later than 15 calendar days after initial receipt of the qualifying information.

Important

Calendar Days vs. Business Days: Regulatory safety reporting timelines are strictly calculated using CALENDAR DAYS , not business days or working days! Weekends, national holidays, and corporate closures do not pause, extend, or alter the 7-day or 15-day statutory clocks.

The "Day 0" Concept: Clock Start Criteria

The reporting clock starts on Day 0 —defined as the exact calendar day when the sponsor (or any individual, affiliate, or Contract Research Organization [CRO] acting on the sponsor's behalf) first receives or becomes aware of the four minimum reporting criteria :

An Identifiable Patient: (e.g., subject identification number, initials, age, or sex).

An Identifiable Reporter: (e.g., investigator name, site staff title, or clinic address).

An Identifiable Investigational Product: (e.g., study drug name, protocol code).

An Adverse Event Outcome Meeting Criteria: (a serious, unexpected adverse event with suspected relationship).

Once these four elements exist in the sponsor's possession, Day 0 is established. The sponsor cannot delay the start of the reporting clock while waiting for complete medical records or hospital discharge summaries.

Site-to-Sponsor Reporting Requirements: ICH E6(R3)

While sponsors bear the legal obligation to report to regulatory authorities, investigative sites are the frontline source of all clinical safety data.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E2A , WMA Declaration of Helsinki, 2024 .